The Canadian VHL Alliance $120,000 Grant with Partner
Cancer Research Society
Winner of the $120,000 Grant, in partnership with the CRS is Dr. Sandra Turcotte, University of Moncton.
Harnessing autophagy and lysosomes as a potential therapeutic approach in hereditary renal cell carcinoma with von Hippel-Lindau disease.
Summary: Von Hippel-Lindau (VHL) is an inherited neoplasia syndrome caused by mutations on the VHL gene and resulting in the development of tumours in different organs such as the eye, ear, adrenal gland, brain, pancreas and kidney. About 70% of VHL patients will develop Renal Cell Carcinoma (RCC) which occurs earlier in their lifetime than other people developing RCC. No curative treatment is available for ccRCC. This project is based on our previous work in kidney cancer and aims to exploit lysosomal vulnerabilities in VHL-mutated cells to develop novel therapeutic strategy for patients with ccRCC associated with VHL disease.